TITLE

EXPRESSION OF C-KIT (CD117) IN NEUROENDOCRINE TUMOURS—A TARGET FOR THERAPY?

AUTHOR(S)
Khan, K.; Kostoula, V.; Savage, K.; Stubbs, M.; McStay, M.; Dhillon, A.P.; Caplin, M.E.
PUB. DATE
April 2003
SOURCE
Gut;Apr2003 Supplement 1, Vol. 52, pA91
SOURCE TYPE
Academic Journal
DOC. TYPE
Article
ABSTRACT
Introduction: Glivec (imatinib mesylate) is currently being used in clinical trials for the treatment of gastrointestinal stromal tumours and is known to specifically inhibit the tyrosine coupled receptor encoded by the c-kit proto-oncogene. Glivec is currently being assessed as a therapeutic possibility in other c-kit positive tumours. Aim: To assess the expression of c-kit (CD117) in neuroendocrine tumours. Methods: Immunohistochemistry was performed on paraffin embedded sections from 62 consecutive NET patients: 36 carcinoid, 16 pancreatic NET, 5 paraganglioma and 5 medullary carcinoma of thyroid. C-kit (CDl17) polyclonal antibody (Dakocytomation) raised against synthesised c-kit peptide was used followed by a horseradish peroxidase detection step for immunohistochemistry. Appropiate negative controls were carried out simultaneously. Results: 36% of carcinoids and 18% of pancreatic NET demonstrated expression of c-kit (CD117). No staining was observed on paragangliomas and medullary carcinoma of thyroid. Conclusion: Immunohistochemical studies have demonstrated the presence of c-kit (CD117) in carcinoid andpancreatic neuroendocrine tumours, with the most expression observedin carcinoid. With limited treatment availability, Glivec may have therapeutic efficacy in the treatment of selected tumour patients.
ACCESSION #
9747891

 

Related Articles

Share

Read the Article

Courtesy of VIRGINIA BEACH PUBLIC LIBRARY AND SYSTEM

Sign out of this library

Other Topics